- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01568593
Comparison of the Efficacy and Safety of T2750 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome
March 7, 2016 updated by: Laboratoires Thea
Comparison of the efficacy and safety of T2750 and Vismed® in the treatment of moderate to severe Dry Eye Syndrome
Study Overview
Study Type
Interventional
Enrollment (Actual)
93
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Paris, France
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed and dated informed consent
- Male or female aged from ≥ 18 years old.
- Known Dry Eye Syndrome requiring artificial tears within the last 3 months prior to study selection.
Exclusion Criteria:
- Best far corrected visual acuity < 1/10
- Severe blepharitis
- Severe Dry Eye
- Eyelid malposition
- Known hypersensitivity to one of the components of the study medications or test products.
- Pregnant or breast-feeding woman.
- Woman of childbearing age (neither menopausal, nor hysterectomised, nor sterilized) not using effective contraception (oral contraceptives, intra-uterine device, contraceptive implant or condoms).
- Inability of patient to understand the study procedures and thus inability to give informed consent.
- Non compliant patient (e.g. not willing to attend the follow-up visits, way of life interfering with compliance).
- Already included once in this study.
- Patient under guardianship.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: T2750
|
1 drop in each eye 3 to 6 times daily during 84 days
|
Active Comparator: Vismed
|
1 drop in each eye 3 to 6 times daily during 84 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Global Ocular Staining (With Oxford Scale - Ranges :0-15)
Time Frame: Baseline and 35 days
|
Change from baseline in the worse eye on Day 35 (decrease of Oxford score = better outcome)
|
Baseline and 35 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2012
Primary Completion (Actual)
March 1, 2013
Study Completion (Actual)
March 1, 2013
Study Registration Dates
First Submitted
March 29, 2012
First Submitted That Met QC Criteria
March 29, 2012
First Posted (Estimate)
April 2, 2012
Study Record Updates
Last Update Posted (Estimate)
April 4, 2016
Last Update Submitted That Met QC Criteria
March 7, 2016
Last Verified
October 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LT2750-PIII-10/11
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Eye Syndromes
-
Singapore National Eye CentreCompleted
-
Singapore National Eye CentreCompleted
-
Alcon ResearchCompletedVisual Performance | Dry Eye Symptoms
-
Alcon ResearchCompletedModerate to Severe Dry Eye
-
Kao (Taiwan) CorporationChang Gung Memorial HospitalCompletedEye Fatigue | Dry Eye SymptomTaiwan
-
Centre for Contact Lens ResearchCoopervision, Inc.CompletedContact Lens Related Dry EyeCanada
-
OptovueCompleted
-
Bausch & Lomb IncorporatedCompletedDry Eye Disease (DED)United States
-
He Eye HospitalCompleted
-
Johnson & Johnson Vision Care, Inc.Completed